Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001)

Clinical Trial ID NCT01295827

PubWeight™ 95.31‹?›

🔗 Visit the page for NCT01295827

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013 18.08
2 PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014 10.39
3 Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015 10.12
4 Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014 8.63
5 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
6 From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012 2.46
7 Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA 2016 2.41
8 PD-1 as a potential target in cancer therapy. Cancer Med 2013 1.98
9 The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther 2015 1.73
10 Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol 2016 1.70
11 Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015 1.67
12 Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol 2015 1.60
13 Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2014 1.59
14 Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer 2018 1.38
15 Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014 1.35
16 Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int 2015 1.25
17 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
18 Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014 1.22
19 Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther 2013 1.22
20 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
21 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
22 Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res 2013 1.12
23 The evolving genomic classification of lung cancer. J Pathol 2014 1.08
24 Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol 2015 1.04
25 New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 2015 1.02
26 Pembrolizumab. J Immunother Cancer 2015 0.99
27 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
28 Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J 2012 0.97
29 The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer 2016 0.92
30 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
31 Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol 2013 0.89
32 Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. Onco Targets Ther 2015 0.88
33 Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res 2014 0.87
34 PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res 2016 0.86
35 Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol 2014 0.85
36 Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology 2014 0.84
37 Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. Biomed Res Int 2015 0.83
38 Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int 2015 0.82
39 Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 2016 0.81
40 Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol 2015 0.81
41 Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol 2016 0.81
42 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
43 Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci 2014 0.80
44 Immunotherapy in lung cancer. Transl Lung Cancer Res 2014 0.80
45 PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014 0.80
46 Pembrolizumab for the treatment of advanced melanoma. Expert Opin Orphan Drugs 2016 0.80
47 Promising targets and current clinical trials in metastatic squamous cell lung cancer. Front Oncol 2014 0.78
48 Immune checkpoint blockade therapy for bladder cancer treatment. Investig Clin Urol 2016 0.78
49 Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 2015 0.77
50 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
51 Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. Onco Targets Ther 2016 0.75
52 Manipulation of Regulatory Cells' Responses to Treatments for Chronic Hepatitis B Virus Infection. Hepat Mon 2016 0.75
53 The role of checkpoints in the treatment of GBM. J Neurooncol 2015 0.75
54 Prime time for immune-checkpoint targeted therapy at ASCO 2015. Oncoimmunology 2015 0.75
55 Cell-Intrinsic Barriers of T Cell-Based Immunotherapy. Trends Mol Med 2016 0.75
Next 100